BIIB - バイオジェン (Biogen Inc.) バイオジェン



symbol BIIB
会社名 Biogen Inc (バイオジェン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 医薬品   医療関連(Health Care)
概要 事業概要 バイオジェン(Biogen Inc.)は生物技術会社である。同社は神経学的疾患、希少疾患、自己免疫疾患の治療製品の発見・開発・製造・提供に従事する。同社は多発性硬化症(MS)の治療用「ECFIDERA」、「AVONEX」、「PLEGRIDY」、「TYSABRI」、「ZINBRYTA」、「FAMPYRA」、重症プラーク乾癬の治療用「FUMADERM」、脊髄性筋萎縮症(SMA)の治療用「SPINRAZA」を含む製品を販売する。同社はまた非ホジキンリンパ腫、慢性リンパ球性白血病(CLL)等の治療用「RITUXAN」に関連するRoche GroupのメンバーであるGenentech、Inc.(Genentech)との共同契約を締結して、CLLと濾胞性リンパ腫の治療用「GAZYVA」、他の抗CD20療法を提供する。同社は製品候補はOCREVUS、バイオシミラー・アダリムマブ、Aducanumab、E2609、BIIB074、BAN2401、オピシヌマブ、CIARA、BIIB061、BIIB054、BIIB067、BIIB068を含む。   バイオジェンはバイオ医薬品企業。神経疾患治療の医薬品の開発・製造・販売に従事する。再発性多発性硬化症(MS)治療薬、クロ―ン病治療薬、非ホジキンリンパ腫と関節リウマチ治療薬などが主要製品。また、潰瘍性大腸炎などの自己免疫疾患のほか、血友病、リンパ性白血病、非ホジキンリンパ腫の治療薬も扱う。本社はマサチュ―セッツ州ケンブリッジ。   At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.
本社所在地 225 Binney Street Cambridge MA 02142 USA
代表者氏名 Stelios Papadopoulos Stelios Papadopoulos
代表者役職名 Independent Chairman of the Board
電話番号 +1 781-464-2000
設立年月日 31229
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 7300人
EBITDA EBITDA(百万ドル) 6760.6
終値(lastsale) 343.03
時価総額(marketcap) 69100940835.5
時価総額 時価総額(百万ドル) 69411.16
売上高 売上高(百万ドル) 12872.4
企業価値(EV) 企業価値(EV)(百万ドル) 72115.36
当期純利益 当期純利益(百万ドル) 4141.8
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Biogen Inc revenues increased 10% to $6.49B. Net income increased 27% to $2.04B. Revenues reflect Product net increase of 5% to $5.28B Revenue Sales of Goods_Services increase of 27% to $933.6M Other Rev from Biz Related Activ. increase from $131.6M to $273M. Net income benefited from Amortization of acquired intangible asse decrease of 63% to $211.3M (expense).



   Global Oligonucleotide Therapy Market Report 2020-2030: COVID-19 Impacts, Growth and Changes -  2021/03/23 14:36:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to's offering. The global oligonucleotide therapy market is expected to decline from $0.9 billion in 2019 to $0.88 billion in 2020 at a compound annual growth rate (CAGR) of -2.1%. Major players in the oligonucleotide therapy market are Alnylam Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Merck
   Don't Lose Sight of Biogen's Depression Drug Amid Focus on Alzheimer's Disease  2021/03/18 13:39:00 Barron's
Truist analyst Robyn Karnauskas argues that investors should be paying more attention to the depression drug that Biogen is developing in partnership with Sage Therapeutics.
   Multiple Sclerosis Therapeutic Market Trend, Technology Innovations and Growth Prediction to 2025 Explore By Major Players Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., AbbVie, Inc.  2021/03/18 07:25:29 OpenPR
The multiple sclerosis therapeutic agents are intended to promote neurorepair and neuroprotection to prevent disease progression. The disease modifying therapeutics are currently under clinical development to specifically target the disease while avoiding frequent therapeutic administrations. A variety of corticosteroids, immunosuppressants
   Covid 19 Analysis on Multiple Sclerosis Therapeutics Market Insights With Major Players: NOVARTIS AG, TEVA PHARMACEUTICAL INDUSTRIES LTD., SANOFI S.A., BAYER AG, PFIZER, INC., BIOGEN IDEC, MERCK & CO., INC., AND ABBVIE, INC.  2021/03/17 10:50:50 OpenPR
Multiple Sclerosis Therapeutics Market report provides key enumeration on the Market status of the Multiple Sclerosis Therapeutics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The research was conducted using
   Biogen's $200M expansion is another boost to NC's growing biopharma sector | WRAL TechWire  2021/03/04 13:23:38 WRAL TechWire
Editor's note: Robin Deacle is Vice President, Corporate Communications, at the North Carolina Biotech Center. RESEARCH TRIANGLE PARK - North Carolina's gene
   Biologics Market - AbbVie, Amgen, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Merck KGaA, Novartis, Pfizer, F. Hoffmann-La Roche Ltd, and Sanofi.  2021/01/21 12:02:51 OpenPR
Coherent Market Insights has recently updated its massive report catalog by adding a fresh study titled "Global Biologics Market – Industry Analysis, Size, Share, Growth, Trends, & Forecast 2020 – 2027". This business intelligence study encapsulates vital details about the
   Global Biosimilars Market Opportunities and Strategies to 2025: Sandoz, Pfizr, Biogen, Biocon, Boehringer Ingelheim, Fresenius Kabi AG, Merck KgaA, Eli Lilly, Mylan  2021/01/18 14:29:47 OpenPR
Biosimilars Market research report gives a detailed information of industry size, share, growth, segments, manufacturers, and advancements, major trends, market drivers, challenges, standardization, deployment models, opportunities, strategies, future roadmap, and 2026 forecast, etc. The report presents a professional and deep
   8 Best Stocks in the Nasdaq This Past Week: Moderna Climbs  2021/01/16 17:31:00 The Street
The best-performing stocks in the Nasdaq this past week included Moderna, Intel, Zoom Video, Biogen among others.
   RBC Capital Stick to Their Hold Rating for Biogen By  2021/01/14 09:08:08
RBC Capital Stick to Their Hold Rating for Biogen
   Canaccord Genuity Stick to Their Buy Rating for Biogen By  2021/01/13 09:03:43
Canaccord Genuity Stick to Their Buy Rating for Biogen
   Augment the Market Growth of Cell and Gene Therapy Industry By Top Players: Amgen, Biogen, Novartis, Pfizer  2020/11/27 14:30:53 OpenPR
Cell and Gene Therapy market are focused on launching novel cell and gene therapies, in order to treat various diseases and address the critical unmet needs of patients. For instance, in June 2011, Fibrocell Technologies, Inc. received approval from the
   STAT+: In major bet, Biogen pays $1.5 billion for rights to a once-failed treatment for depression  2020/11/27 14:04:35 STAT News
Biogen, placing a major bet on a once-failed treatment, is paying $1.53 billion for the commercial rights to a Sage Therapeutics’ oral depression drug.
   Biogen, Sage Therapeutics Enter $1.5 Billion Deal To Develop, Sell Neurological Treatments  2020/11/27 13:36:13 CNN-News18
Biogen Inc will take a $650 million stake in Sage Therapeutics and pay $875 million in upfront payment as they jointly develop and sell treatments for neurological disorder, the two companies said on Friday.
   Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders - Stocks News Feed  2020/11/27 12:30:00 Stocks News Feed
Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S. Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S., excluding rights to zuranolone in Japan, Taiwan and South Korea Sage Therapeutics to receive $1.525 billion in cash comprised of an… Read More »Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
   Global Cancer Antibody Drug Conjugates Market to Witness Robust Expansion Throughout the Forecast Period 2020-2027| Biogen Idec, Merck, Novartis, AbbVie, Stem CentRx, Roche  2020/11/26 12:55:15 OpenPR
Overview: In recent years, cancer antibody conjugates have grown up as an emerging development frontier for pharmaceutical companies involved in research and development of medications for cancer. Monoclonal antibodies offer high therapeutic effectiveness and minimal side effects. They also have very

 関連キーワード  (医薬品 米国株 バイオジェン BIIB Biogen Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)